J&J reports comprehensive emissions data with third-party verification, but Scope 3 stagnation undermines climate trajectory. Nature and biodiversity disclosure is minimal despite sourcing palm oil linked to deforestation. Systemic governance failures—90,000+ talc lawsuits, $25B+ in penalties—reflect institutional weakness that extends beyond environmental claims.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Energy Source (7/10, 7/10). Weakest on Nature & Biodiversity Impact and Controversies & Red Flags (3/10, 4/10).
14 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Among the 11 major healthcare / pharmaceuticals brands we've scored, Johnson & Johnson sits 8th of 11.
Score history begins 8 February 2026.
As Johnson & Johnson's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Johnson & Johnson is a diversified healthcare conglomerate headquartered in New Jersey, operating across pharmaceuticals, medical devices, and consumer health. Founded in 1976 as a public company (though the family business dates to 1886), it ranks among the world's largest by market capitalization and employs over 130,000 globally. The company faces mounting product liability exposure alongside sustainability transition pressures.
Comparable pharma giant with similar scale, emissions complexity, and governance scrutiny pressures.
View breakdown →Swiss pharma peer with higher renewable energy penetration and different supply-chain accountability baseline.
View breakdown →Diversified consumer-healthcare conglomerate with similar palm oil supply-chain deforestation criticism and stronger circular packaging commitments.
View breakdown →Consumer health and household products competitor with comparable packaging circularity targets and greenwashing litigation exposure.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.